Generic Arazlo Availability
Last updated on Apr 10, 2025.
Arazlo is a brand name of tazarotene topical, approved by the FDA in the following formulation(s):
ARAZLO (tazarotene - lotion;topical)
-
Manufacturer: BAUSCH
Approval date: December 18, 2019
Strength(s): 0.045% [RLD]
Is there a generic version of Arazlo available?
No. There is currently no therapeutically equivalent version of Arazlo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arazlo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical compositions and methods for treating skin diseases
Patent 11,311,482
Issued: April 26, 2022
Inventor(s): Angel; Arturo et al.
Assignee(s): BAUSCH HEALTH US, LLC (Bridgewater, NJ)Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion. The compositions are used to treat skin diseases, such as acne vulgaris.
Patent expiration dates:
- May 11, 2038✓
- May 11, 2038
-
Topical compositions and methods for treating psoriasis
Patent 11,679,116
Issued: June 20, 2023
Inventor(s): Dow; Gordon J. et al.
Assignee(s): Bausch Health Ireland Limited (Dublin, IE)Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.
Patent expiration dates:
- June 6, 2036✓
- June 6, 2036
-
Topical compositions and methods for treating skin diseases
Patent 12,128,137
Issued: October 29, 2024
Inventor(s): Angel; Arturo et al.
Assignee(s): BAUSCH HEALTH IRELAND LIMITED (Dublin, IE)Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion. The compositions are used to treat skin diseases, such as acne vulgaris.
Patent expiration dates:
- May 11, 2038✓✓
- May 11, 2038
More about Arazlo (tazarotene topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (13)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical acne agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
